A citation-based method for searching scientific literature

Karl Sebastian Johansson, David Peick Sonne, Filip Krag Knop, Mikkel Bring Christensen. Expert Opin Drug Discov 2020
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bruce Bode, Kaj Stenlöf, Daniel Sullivan, Albert Fung, Keith Usiskin. Hosp Pract (1995) 2013
163
50

Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
80
50

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki, Gang Cheng, Kosuke Shiki, Yuki Miyamoto, Fernando Solimando, Christopher Lee, Jisoo Lee, Jyothis George. Diabetes Obes Metab 2018
18
50


Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
54
50

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba,[...]. Diabetes Care 2015
146
50

Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy.
Gopika G Nair, Emmanuel S Tzanakakis, Matthias Hebrok. Nat Rev Endocrinol 2020
8
50

Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe, Maki Gouda. Diabetes Obes Metab 2017
32
50

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
77
50

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
274
50


Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Linong Ji, Yanmei Liu, Heng Miao, Yongli Xie, Ming Yang, Wei Wang, Yuting Mu, Ping Yan, Sharon Pan, Brett Lauring,[...]. Diabetes Obes Metab 2019
17
50



Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
212
50

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
254
50

Type 1 diabetes mellitus in pediatrics.
David W Cooke, Leslie Plotnick. Pediatr Rev 2008
59
50

Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department.
Elena-Codruța Dobrică, Mihnea-Alexandru Găman, Matei-Alexandru Cozma, Ovidiu Gabriel Bratu, Anca Pantea Stoian, Camelia Cristina Diaconu. Medicina (Kaunas) 2019
20
50

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Darcy Hille, Yuqin Liao, Susan Huyck, Gregory Golm, Steven G Terra,[...]. Diabetes Obes Metab 2018
71
50

Standardization of HbA1c and Optimal Range of Monitoring.
Kor Miedema. Scand J Clin Lab Invest Suppl 2005
28
50

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
Theo Vos, Abraham D Flaxman, Mohsen Naghavi, Rafael Lozano, Catherine Michaud, Majid Ezzati, Kenji Shibuya, Joshua A Salomon, Safa Abdalla, Victor Aboyans,[...]. Lancet 2012
50

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring,[...]. Diabetes Obes Metab 2018
75
50

Comparison between a rapid glycohaemoglobin (HbA1c) immunoassay and other indices of glycaemic control.
E Le Marois, F Bruzzo, G Reach, F Guyon, J Luo, J Boillot, G Slama, J L Selam. Acta Diabetol 1996
2
50

Is haemoglobin A1c a step forward for diagnosing diabetes?
Eric S Kilpatrick, Zachary T Bloomgarden, Paul Z Zimmet. BMJ 2009
57
50

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
183
50



Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Wenying Yang, Ping Han, Kyung-Wan Min, Bei Wang, Traci Mansfield, Caroline T'Joen, Nayyar Iqbal, Eva Johnsson, Agata Ptaszynska. J Diabetes 2016
29
50


Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
505
50

Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.
Irene Romera, Francisco Javier Ampudia-Blasco, Antonio Pérez, Bernat Ariño, Egon Pfarr, Sanja Giljanovic Kis, Ebrahim Naderali. Endocrinol Nutr 2016
7
50

Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi, Paraskevi Salpea, Suvi Karuranga, Inga Petersohn, Belma Malanda, Edward W Gregg, Nigel Unwin, Sarah H Wild, Rhys Williams. Diabetes Res Clin Pract 2020
42
50



Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
232
50

Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis.
Mao-Bing Chen, Rui-Jun Xu, Qi-Han Zheng, Xu-Wen Zheng, Hua Wang. Medicine (Baltimore) 2020
2
50

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
J Picot, J Jones, J L Colquitt, E Gospodarevskaya, E Loveman, L Baxter, A J Clegg. Health Technol Assess 2009
547
50

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Christopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans-Juergen Woerle, Uli C Broedl. Clin Ther 2015
55
50

Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Wenying Yang, Jianhua Ma, Yiming Li, Yanbing Li, Zhiguang Zhou, Jae Hyeon Kim, June Zhao, Agata Ptaszynska. J Diabetes 2018
21
50


Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ryuichi Ohgaki, Ling Wei, Kazunori Yamada, Taiki Hara, Chiaki Kuriyama, Suguru Okuda, Kiichiro Ueta, Masaharu Shiotani, Shushi Nagamori, Yoshikatsu Kanai. J Pharmacol Exp Ther 2016
33
50

Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
666
50

The effect of publication bias on the Q test and assessment of heterogeneity.
Hilde E M Augusteijn, Robbie C M van Aert, Marcel A L M van Assen. Psychol Methods 2019
17
50



The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis, Pantelis Sarafidis. Curr Med Chem 2020
9
50

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
395
50

Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck.
Burkhard M Helmke, Christoph Reisser, Mario Idzko, Gerhard Dyckhoff, Christel Herold-Mende. Oral Oncol 2004
21
50

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
20
50

Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight.
Michael Rosenbaum, Jules Hirsch, Dympna A Gallagher, Rudolph L Leibel. Am J Clin Nutr 2008
236
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.